Akari Therapeutics, Plc (AKTX)
Company Info
Highlights
$40.72M
-$14.08M
$0.85 - $4.40
$80.00
0.44%
2.71
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Akari Therapeutics, Plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Akari Therapeutics, Plc (AKTX) returned 9.84% year-to-date (YTD) and -7.59% over the past 12 months.
AKTX
9.84%
16.52%
-44.86%
-7.59%
-48.18%
N/A
^GSPC (Benchmark)
-3.70%
13.67%
-5.18%
9.18%
14.14%
10.43%
Monthly Returns
The table below presents the monthly returns of AKTX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -10.66% | -20.18% | 42.53% | 16.13% | -6.94% | 9.84% | |||||||
| 2024 | -16.03% | -10.31% | -20.64% | -17.43% | 11.30% | 57.53% | 43.33% | -1.03% | -22.98% | -18.64% | -49.58% | 0.83% | -60.90% |
| 2023 | -0.66% | -26.09% | -47.33% | -0.33% | -2.32% | -3.90% | 46.82% | -36.90% | 25.40% | -13.67% | -13.49% | 5.76% | -66.80% |
| 2022 | -8.67% | -1.46% | -11.11% | -0.83% | -1.68% | -14.54% | 14.01% | 4.39% | -47.06% | -26.06% | 18.63% | -14.97% | -68.67% |
| 2021 | 36.76% | 32.41% | -21.19% | -21.97% | -12.86% | -3.62% | -6.36% | 13.58% | -11.41% | 1.84% | -1.81% | -7.98% | -18.92% |
| 2020 | 2.86% | 2.22% | -21.20% | 32.41% | 6.25% | 6.86% | -7.80% | -14.43% | 1.16% | -13.79% | 6.67% | 15.62% | 5.71% |
| 2019 | 28.01% | -9.94% | 97.79% | -0.00% | -46.93% | 6.32% | -6.93% | 10.64% | -17.79% | 11.11% | 8.42% | -15.05% | 11.46% |
| 2018 | -33.95% | -31.82% | -6.67% | 4.95% | -3.66% | 5.98% | -1.54% | -2.08% | 36.17% | -29.69% | -0.56% | -12.29% | -63.74% |
| 2017 | 13.64% | -18.62% | 70.05% | 35.41% | -59.11% | -24.80% | 0.87% | -23.66% | 72.96% | -30.13% | 13.29% | -10.91% | -38.49% |
| 2016 | -4.57% | -30.19% | 44.93% | 22.86% | -12.21% | -10.66% | -31.06% | 1.72% | -10.04% | 11.05% | -24.34% | -1.54% | -51.45% |
| 2015 | -23.83% | -20.40% | 1.57% | -25.25% | -53.97% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of AKTX is 55, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Akari Therapeutics, Plc (AKTX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Akari Therapeutics, Plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Akari Therapeutics, Plc was 99.86%, occurring on Feb 28, 2025. The portfolio has not yet recovered.
The current Akari Therapeutics, Plc drawdown is 99.79%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.86% | Sep 22, 2015 | 2327 | Feb 28, 2025 | — | — | — |
Volatility
Volatility Chart
The current Akari Therapeutics, Plc volatility is 22.60%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Akari Therapeutics, Plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Akari Therapeutics, Plc, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 100.0% positive surprise.
Valuation
The Valuation section provides an overview of how Akari Therapeutics, Plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for AKTX, comparing it with other companies in the Biotechnology industry. Currently, AKTX has a P/E ratio of 0.0. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for AKTX compared to other companies in the Biotechnology industry. AKTX currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for AKTX relative to other companies in the Biotechnology industry. Currently, AKTX has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for AKTX in comparison with other companies in the Biotechnology industry. Currently, AKTX has a P/B value of 1.8. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |